97 Matching Annotations
  1. Last 7 days
  2. Oct 2021
  3. Sep 2021
    1. Kraemer, M. U. G., Hill, V., Ruis, C., Dellicour, S., Bajaj, S., McCrone, J. T., Baele, G., Parag, K. V., Battle, A. L., Gutierrez, B., Jackson, B., Colquhoun, R., O’Toole, Á., Klein, B., Vespignani, A., COVID-19 Genomics UK (COG-UK) Consortium‡, Volz, E., Faria, N. R., Aanensen, D. M., … Pybus, O. G. (2021). Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence. Science, 373(6557), 889–895. https://doi.org/10.1126/science.abj0113

  4. Aug 2021
    1. Prof. Christina Pagel on Twitter: “THREAD latest on B.1.617.2 variant in England: B.1.617.2 (1st discovered in India) is now dominant in England. Here is a thread summarising latest PHE report and Sanger local data. TLDR: it is NOT good news. 1/7” / Twitter. (n.d.). Retrieved August 24, 2021, from https://twitter.com/chrischirp/status/1399333330286415876

    1. Marc Lipsitch. (2021, July 20). At the risk of boiling down too much and certainly losing some detail, one way to summarize this wonderful thread is that when we think about vaccine effectiveness, we should think of 4 key variables: 1 which vaccine, 2 age of the person, 3 how long after vax, 4 vs what outcome. [Tweet]. @mlipsitch. https://twitter.com/mlipsitch/status/1417595538632060931

  5. Jul 2021
    1. Carl T. Bergstrom. (2021, May 27). An update on the B.1.617.2 lineage. I’m concerned. Not because of reduced vaccine efficacy, but simply because a further increase in transmissibility above B.1.1.7 would be quite bad news for countries where vaccination is low and for hopes of near-elimination everywhere. [Tweet]. @CT_Bergstrom. https://twitter.com/CT_Bergstrom/status/1398029743954432005

    2. Meaghan Kall 🏳️‍🌈 on Twitter: “The updated cumulative growth curves showing continued exponential growth of B.1.617.2.. Https://t.co/3fmEwU7cP3” / Twitter. (n.d.). Retrieved July 2, 2021, from https://twitter.com/kallmemeg/status/1397981951907217411

    1. Adam Kucharski on Twitter: “Useful data 👇– quick look suggests odds ratio for detection of B.1.617.2 relative to non-B.1.617.2 in vaccinated group compared to controls is 2.7 (95% CI: 0.7-10) after one dose and 1.2 (0.4-3.6) after two...” / Twitter. (n.d.). Retrieved July 2, 2021, from https://twitter.com/AdamJKucharski/status/1400443351908892675?s=20

  6. Jun 2021
    1. Lewis Spurgin on Twitter: “Perhaps an under appreciated point with the B.1.617.2 variant is that regional PHE teams and local authorities across the country are putting in heroic amounts of effort to break chains of transmission. (1/2)” / Twitter. (n.d.). Retrieved June 27, 2021, from https://twitter.com/LewisSpurgin/status/1395827267297759234

    1. Deepti Gurdasani on Twitter: “I’m still utterly stunned by yesterday’s events—Let me go over this in chronological order & why I’m shocked. - First, in the morning yesterday, we saw a ‘leaked’ report to FT which reported on @PHE_uk data that was not public at the time🧵” / Twitter. (n.d.). Retrieved June 27, 2021, from https://twitter.com/dgurdasani1/status/1396373990986375171

    1. (1) ReconfigBehSci on Twitter: ‘RT @ScottGottliebMD: The U.K. is experiencing a growing surge of COVID infections with a new variant that appears more pathogenic, and that…’ / Twitter. (n.d.). Retrieved 21 June 2021, from https://twitter.com/SciBeh/status/1402048528189300737

    1. Prof. Christina Pagel. (2021, May 3). THREAD: Update on B.1.617 (‘India’) variant in England using latest data from the Sanger institute. This data excludes sequenced cases from travellers & surge testing so ‘should be an approximately random sample of positive tests in the community’ TLDR: warning signs! 1/10 https://t.co/0UzhM8GNIA [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1389273187586875396

    1. Wall, E. C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P., Hatipoglu, E., Ngai, Y., Hussain, S., Nicod, J., Goldstone, R., Ambrose, K., Hindmarsh, S., Beale, R., Riddell, A., Gamblin, S., Howell, M., … Bauer, D. L. (2021). Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(21)01290-3

  7. May 2021
    1. Prof. Christina Pagel on Twitter: “So Hancock confirms that B.1.617.2 (‘India’ variant) is now dominant in England. Harries says we must remain ‘vigilant’. What does vigilant even mean? That we watch very carefully as a new, more dangerous, variant takes over cos it was so fun last time? Yeah, I’m pissed off” / Twitter. (n.d.). Retrieved May 28, 2021, from https://twitter.com/chrischirp/status/1397951741283405825

    1. Hilda Bastian, PhD. (2021, February 6). Unofficial unnamed AstraZeneca insider says they are doing the interim analysis for the US trial of the Oxford vaccine. AstraZeneca spokesperson says 4-6 weeks till data release. Https://t.co/VUHgbHN02d One is wrong? Or they’ll release only when have FDA minimum follow-up? Https://t.co/LgjfX8AIti [Tweet]. @hildabast. https://twitter.com/hildabast/status/1357862227106095105

    1. Carlos del Rio. (2021, April 7). U.K. variant now dominant form of COVID in US ⁦@CDCDirector⁩ As predicted B.1.1.7 is now the predominant SARS-CoV-2 strain in the US. Let’s remember it is much more transmissible and likely also more severe. Vaccines do cover it. ⁦@ajc⁩ https://t.co/Wc4oaYkxqR [Tweet]. @CarlosdelRio7. https://twitter.com/CarlosdelRio7/status/1379816377356333057

  8. Apr 2021
    1. Trevor Bedford. (2021, January 14). After ~10 months of relative quiescence we’ve started to see some striking evolution of SARS-CoV-2 with a repeated evolutionary pattern in the SARS-CoV-2 variants of concern emerging from the UK, South Africa and Brazil. 1/19 [Tweet]. @trvrb. https://twitter.com/trvrb/status/1349774271095062528

    1. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leschinsky, M., Dror, S. K., Bergerzon, G., Gadban, H., Gadban, F., Eliassian, E., Shimron, O., Saleh, L., Ben-Zvi, H., Amichay, D., Ben-Dor, A., … Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. MedRxiv, 2021.04.06.21254882. https://doi.org/10.1101/2021.04.06.21254882

    1. Lee, L. Y., Rozmanowski, S., Pang, M., Charlett, A., Anderson, C., Hughes, G. J., Barnard, M., Peto, L., Vipond, R., Sienkiewicz, A., Hopkins, S., Bell, J., Crook, D. W., Gent, N., Walker, A. S., Peto, T. E., & Eyre, D. W. (2021). SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission. MedRxiv, 2021.03.31.21254687. https://doi.org/10.1101/2021.03.31.21254687

  9. Mar 2021
    1. Grint, D. J., Wing, K., Williamson, E., McDonald, H. I., Bhaskaran, K., Evans, D., Evans, S. J., Walker, A. J., Hickman, G., Nightingale, E., Schultze, A., Rentsch, C. T., Bates, C., Cockburn, J., Curtis, H. J., Morton, C. E., Bacon, S., Davy, S., Wong, A. Y., … Eggo, R. M. (2021). Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England. MedRxiv, 2021.03.04.21252528. https://doi.org/10.1101/2021.03.04.21252528